Please assess the completion status of the following clinical trial:

Trial Title: Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males ages 18- 50 (inclusive)~* Ability to swallow oral medication~* Informed consent~* Willing and able to participate in the study for 28 days~For the G6PDd participants:~* G6PDd defined by Carestart 3 rapid diagnostic test or~* The OSMMR2000 G6PD qualitative test~For the G6PDn participants:~* G6PDn defined by Carestart 3 rapid diagnostic test or~* The OSMMR2000 G6PD qualitative test~Exclusion Criteria:~* Moderate to severe anemia (Hb \< 10 g/dL)~* Malaria infection by blood smear~* Individuals with known positive HIV test~* Individuals with known positive hepatitis B test.~* Known allergy to study drugs~* Current use of medication (for tuberculosis, HIV, or any drugs that have hemolytic potential in G6PDd individuals including sulphonamides, dapsone, nitrofurantoin, nalidixic acid, ciprofloxacin, methylene blue, toluidine blue, phenazopyridine, and co-trimoxazole)~* The individual is unwilling to abstain from the ingestion of grapefruit-containing products from 72 hours prior to the start of dosing until the study is complete~* Use of antimalarials within 2 weeks before contact with the study team as reported by the patient~* History of blood transfusion or a bleed of \> 500 mLs within the last 3 months, as reported by the patient~* Reported history of high alcohol intake (\> 14 units per week, each unit is equivalent to 10 g of alcohol (1 glass of wine or 1 bottle of beer or one shot of distilled spirits), within 6 months of study as reported by the patient~* Reported use of illicit drugs (marijuana, heroin, cocaine, methamphetamine) or dependence within 6 months of study, as reported by the patient~* Participants who vomit within 1 hour after administration of primaquine (will be removed from the analysis and will not count towards the total sample size, though they will be followed as any other enrolled individual)~* Already enrolled in this study.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- A: 0.40 mg/kg PQ G6PDd (Type: EXPERIMENTAL): 0.40 mg/kg of primaquine (as a single dose) in G6PD-deficient individuals
- B: PQ in G6PDd (Type: EXPERIMENTAL): A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
- C: PQ in G6PDd (Type: EXPERIMENTAL): A single dose of primaquine in G6PD-deficient men, exact dose to be decided by DSMB based on findings in previous dose group. The minimum change in dose from the last study dose is 0.05 mg/kg, and the maximum change is 0.20 mg/kg of primaquine). Dose is not to exceed 0.75 mg/kg primaquine.
- D: PQ G6PDn (Type: EXPERIMENTAL): A single dose of primaquine in G6PD-normal men, at the highest tolerable dose determined by the DSMB, from previous dose groups.

Based on this trial design, predict the completion outcome and termination type (if applicable).